TrialDrug design, development and therapy2024

A Randomized, Double-Blind, Parallel-Group Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of CMAB015, a Candidate Secukinumab Biosimilar, with Its Reference Product Cosentyx

Feng Yao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.